RESEARCH TRIANGLE PARK, N.C. & SANTA CLARA, Calif.--(BUSINESS WIRE)--GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced results from a Phase II clinical trial of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults. GSK1838262 did not demonstrate a statistically significant improvement on the primary endpoint when compared to placebo, based on the change from baseline to end of treatment on the Pain Intensity-Numerical Rating Scale (PI-NRS). The pregabalin active control arm also did not differentiate from placebo on this same endpoint. The failure of the study to demonstrate a statistically significant benefit on the primary endpoint may be a consequence of the unexpectedly high placebo response rate observed in the study.
This 14-week, double-blind, placebo-controlled study enrolled 421 patients who were diagnosed with either Type 1 or Type 2 diabetes mellitus with signs and symptoms of DPN. Patients were randomized to receive either 1200 mg/day, 2400 mg/day or 3600 mg/day of GSK1838262 administered in divided doses twice daily, 300 mg/day of pregabalin as an active control, administered in divided doses three times daily, or placebo.
Throughout the study, GSK1838262 was generally well tolerated; the two most frequently reported adverse events were dizziness and somnolence.
“Although we are disappointed that neither GSK1838262 nor pregabalin demonstrated a clear clinical benefit over placebo in this study, we will be evaluating the study results further in order to determine our next steps,” said Atul Pande, M.D., senior vice president, GlaxoSmithKline Neurosciences Medicines Development Center.
Ronald W. Barrett, Ph.D., chief executive officer of XenoPort, stated, “A high placebo response is not uncommon in DPN studies, and this has been a contributing factor to several failed studies testing different drugs in this patient population. The failure of pregabalin in this study makes it difficult to draw definitive conclusions about the efficacy of GSK1838262. We are encouraged by the observation that all doses of GSK1838262 were generally well tolerated, particularly since the 3600 mg dose represents the highest dose tested in a study of this length.”
Conference Call and Webcast Information
XenoPort will host a conference call at 8:30 a.m. Eastern Time today. To access the conference call via the Internet, go to www.XenoPort.com. To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 1-706-679-1417.
The replay of the conference call may be accessed after 11:30 a.m. Eastern Time today via the Internet, at www.XenoPort.com, or via phone at 1-800-642-1687 for domestic callers or 1-706-645-9291 for international callers. The reference number to enter the call and the replay of the call is 97281294
GSK1838262 is a new chemical entity that is designed to improve upon the pharmacokinetics of gabapentin by taking advantage of high-capacity transport mechanisms in the gastrointestinal tract to improve absorption.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
XenoPort – is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in partnership with Astellas Pharma Inc. and GSK. XenoPort’s product candidates are also being studied for the potential treatment of moderate-to-severe primary restless legs syndrome, gastroesophageal reflux disease, migraine headaches, spasticity related to spinal cord injury, acute back spasms and Parkinson’s disease. To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
GlaxoSmithKline cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’ s Annual Report on Form 20-F for 2007. Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
Contacts
GlaxoSmithKline US Media enquiries: Holly Russell, 919-483-2839 Mary Anne Rhyne, 919-483-2839 US Analyst/ Investor enquiries: Tom Curry, 215-751-5419 Jen Hill Baxter, 215-751-7002 or XenoPort XenoPort Analyst/Investor and Media enquiries: Jackie Cossmon, 408-616-7220
